- ByInvesting.com-
Investing.com -- European insurers may offer relative defensiveness within financial stocks as the U.S.-Iran conflict escalates,...
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 323.4 | 325.8 | 318.4 | -6.7 | -2.03% | 1.34M | ||
| 969.2 | 982.4 | 965.0 | -14.0 | -1.42% | 197.01K | ||
| 1,641.0 | 1,674.5 | 1,622.0 | +5.5 | +0.34% | 329.74K | ||
| 237.4 | 237.8 | 224.3 | -0.6 | -0.25% | 8.39M | ||
| 16,910 | 17,000 | 16,175 | +1,235 | +7.88% | 46.77K | ||
| 372.9 | 376.0 | 369.2 | -2.6 | -0.69% | 778.28K | ||
| 16,680 | 16,790 | 16,030 | +1,180 | +7.61% | 9.54K | ||
| 801.0 | 819.0 | 788.0 | -18.5 | -2.26% | 214.83K | ||
| 1,867.5 | 1,903.0 | 1,838.0 | +19.0 | +1.03% | 157.34K | ||
| 550.0 | 555.0 | 539.0 | -10.5 | -1.87% | 132.37K | ||
| 160.8 | 164.3 | 157.6 | -1.7 | -1.05% | 2.91M | ||
| 196.4 | 199.0 | 191.5 | -0.4 | -0.20% | 577.65K | ||
| 156.4 | 157.0 | 153.2 | -0.2 | -0.13% | 1.05M | ||
| 484.8 | 488.1 | 479.5 | -3.2 | -0.66% | 336.76K | ||
| 930.0 | 935.5 | 923.0 | -18.5 | -1.95% | 105.68K | ||
| 486.2 | 499.1 | 480.0 | -13.8 | -2.76% | 399.33K | ||
| 198 | 205 | 198 | -11 | -5.25% | 649.75K | ||
| 367.00 | 368.30 | 358.10 | +3.20 | +0.88% | 208.63K | ||
| 220.20 | 223.00 | 218.40 | -4.80 | -2.13% | 438.65K | ||
| 150.85 | 151.65 | 147.30 | +0.85 | +0.57% | 1.39M |
Investing.com -- European insurers may offer relative defensiveness within financial stocks as the U.S.-Iran conflict escalates,...
Investing.com -- Goldman Sachs on Monday downgraded Danish drugmaker Novo Nordisk to “neutral” from “buy”...
Investing.com -- Novo Nordisk (CSE:NOVOb) announced Monday it will invest 432 million euros ($506.43 million) to expand its...
Novo Nordisk A/S experienced a dramatic stock decline following the company’s surprise pre-release of its 2026 forecast late...
It’s no secret that the Trump administration is skeptical, to put it mildly, of alternative energy. If that was a signal for...
Novo Nordisk A/S (NYSE:NVO) announced that CEO Lars Fruergaard Jørgensen is stepping down amid mounting challenges, with the...
No Earning Reports have been scheduled